Kezar doses first patient in advanced solid tumor malignancies study

Kezar Logo

Kezar Life Sciences (NASDAQ:KZR) dosed the first patient in a Phase 1 clinical trial evaluating KZR-261, a broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon.

“We believe KZR-261 has a differentiated therapeutic profile, which could translate into broad potential across the oncology landscape,” John Fowler, co-founder and CEO of Kezar, said in a statement. KZR-261 is the first clinical candidate from Kezar’s protein secretion platform.

The open-label, multicenter, Phase 1 study is being conducted in two parts, dose escalation and dose expansion, and is designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics to determine doses for Phase 2 studies, as well as to explore the preliminary anti-tumor activity of KZR-261 in subjects with locally advanced or metastatic disease for whom no therapeutics are currently available. 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.